OMER - Omeros Corporation

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
18.95
-0.18 (-0.94%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.13
Open19.48
Bid17.56 x 200
Ask20.70 x 500
Day's Range18.86 - 19.68
52 Week Range7.80 - 27.09
Volume438,884
Avg. Volume686,013
Market Cap907.66M
Beta3.86
PE Ratio (TTM)-12.94
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
    Zacks23 hours ago

    Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU

    Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.

  • Omeros Corporation (OMER) Case Report Presented at EBMT Annual Meeting
    SmarterAnalystyesterday

    Omeros Corporation (OMER) Case Report Presented at EBMT Annual Meeting

    Omeros Corporation (NASDAQ:OMER) announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and graft-versus-host disease (GvHD), which both resolved following OMS721 treatment. This case was presented this morning at the European Society for Blood and Marrow Transplantation (EBMT) Crash Course on Diagnosis and Treatment of Noninfectious Complications after HCT in Granada, Spain. The presentation, “Effective Treatment of GvHD-Associated Transplant-Associated Microangiopathy with a Novel Inhibitor of the Lectin Pathway of Complement,” was made by Chiara Caprioli, M.D. of the Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, in Bergamo, Italy.

  • Capital Cube3 days ago

    ETFs with exposure to Omeros Corp. : October 18, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • What You Must Know About Omeros Corporation’s (OMER) Risks
    Simply Wall St.15 days ago

    What You Must Know About Omeros Corporation’s (OMER) Risks

    If you are a shareholder in Omeros Corporation’s (NASDAQ:OMER), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • MarketWatch16 days ago

    Omeros shares surge 10% after settlement with Endo delays generic to 2032

    Omeros Corporation shares surged as much as 10% in morning trade Thursday, before paring some gains, after the company announced a settlement with Endo International PLC's Par Pharmaceutical Inc. that ...

  • Capital Cube18 days ago

    ETFs with exposure to Omeros Corp. : October 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • 3 Stocks Up 30% or More Year to Date That Could Be Just Getting Started
    Motley Fool23 days ago

    3 Stocks Up 30% or More Year to Date That Could Be Just Getting Started

    These stocks are already beating the market, but don't take profits just yet.

  • Capital Cube29 days ago

    ETFs with exposure to Omeros Corp. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Omeros Corp. : September 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Omeros Corp. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Omeros Corp. :OMER-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube2 months ago

    Omeros Corp. :OMER-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Omeros Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Omeros Corp. – Pfizer Inc., BioTime, Inc., Johnson & Johnson, Acura Pharmaceuticals, Inc., Akorn, Inc., DURECT Corporation and Pain Therapeutics, Inc. (PFE-US, BTX-US, JNJ-US, ACUR-US, AKRX-US, DRRX-US and PTIE-US) ... Read more (Read more...)

  • TheStreet.com2 months ago

    Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

    The Seattle firm said Aug. 21 it completed an underwritten public offering of 3 million shares priced at $22.75 apiece.

  • Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : August 22, 2017
    Capital Cube2 months ago

    Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : August 22, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Omeros Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • MarketWatch2 months ago

    Omeros's stock sinks after share offering prices at a discount

    Shares of Omeros Corp. sank 8% in morning trade Tuesday, after the biopharmaceutical company took advantage of a recent surge in price to launch a public offering of shares. The company said late Monday ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of OMER earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 Omeros Corp Earnings Call

  • Associated Press2 months ago

    Omeros reports 2Q loss

    The Seattle-based company said it had a loss of 33 cents per share. Losses, adjusted for non-recurring costs, were 23 cents per share. The drug developer posted revenue of $17.2 million in the period. ...

  • 3 Stocks That Could Put Nvidia's Returns to Shame
    Motley Fool3 months ago

    3 Stocks That Could Put Nvidia's Returns to Shame

    Stocks with the potential for returns anywhere near what NVIDIA has given in the last few years are rare, but we have three picks that have the potential for massive increases.

  • TheStreet.com4 months ago

    Biotech Movers: BioCryst, Omeros, Radius Health

    BioCryst Pharmaceuticals, Omeros and Radius Health were among the were among the biotech stock movers in premarket trading on July 3.

  • SmarterAnalyst4 months ago

    Omeros Corporation (OMER) Accuses Short Seller of Manipulation

    Omeros Corporation (NASDAQ:OMER) shares tumbled nearly 9% yesterday, following a bearish report issued by Art Doyle research, a group that identifies as having a short position in Omeros’ stock. "As we will show you in this report, Omeros tried to do subcutaneous delivery in their Phase 1 for OMS721. Omeros doesn’t have subcutaneous in Phase 2 and they never will.

  • Here's Why Omeros Corporation Fell as Much as 14.8% Today
    Motley Fool4 months ago

    Here's Why Omeros Corporation Fell as Much as 14.8% Today

    The small biopharma is cooling off after huge gains this month.

  • These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing?
    Motley Fool4 months ago

    These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing?

    Find out if these biotech stock rockets have any more fuel in the tank.